Published February 14, 2023 | Version v1
Journal article Open

Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients

  • 1. Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Napoli, Italy
  • 2. A.O.R.N. Santobono-Pausilipon, Napoli Italy
  • 3. Laboratory Medicine Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Napoli, Italy
  • 4. UOC Biochimica Chimica, AORN Ospedale dei Colli P.O. Monaldi, Napoli, Italy
  • 5. JPT Peptide Technologies GmbH, Berlin. Germany
  • 6. Innovative Immunological Models, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", via Mariano Semmola, 80131 Napoli, Italy

Description

Background: The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical course with some patients being asymptomatic whereas others experiencing severe respiratory distress, or even death. We aimed to evaluate the immunoglobulin G (IgG) response towards linear peptides on a peptide array containing sequences from SARS-CoV-2, Middle East respiratory syndrome-related coronavirus (MERS) and common-cold coronaviruses 229E, OC43, NL63 and HKU1 antigens, in order to identify immunological indicators of disease outcome in SARS-CoV-2 infected patients.

Methods: We included in the study 79 subjects, comprising 19 pediatric and 30 adult SARS-CoV-2 infected patients with increasing disease severity, from mild to critical illness, and 30 uninfected subjects who were vaccinated with one dose of SARS-CoV-2 spike mRNA BNT162b2 vaccine. Serum samples were analyzed by a peptide microarray containing 5,828 overlapping 15-mer synthetic peptides corresponding to the full SARS-CoV-2 proteome and selected linear epitopes of spike (S), envelope (E)  and membrane (M) glycoproteins as well as nucleoprotein (N) of MERS, SARS and coronaviruses 229E, OC43, NL63 and HKU1 (isolates 1, 2 and 5).

Results: All patients exhibited high IgG reactivity against the central region and C-terminus peptides of both SARS-CoV-2 N and S proteins. Setting the threshold value for serum reactivity above 25,000 units, 100% and 81% of patients with severe disease, 36% and 29% of subjects with mild symptoms, and 8% and 17% of children younger than 8-years reacted against N and S proteins, respectively. Overall, the total number of peptides in the SARS-CoV-2 proteome targeted by serum samples was much higher in children compared to adults. Notably, we revealed a differential antibody response to SARS-CoV-2 M peptides between adults, mainly reacting against C-terminus M antigens, and children, which were highly responsive to N-terminus M epitopes. In addition, IgG signals against NS7B, NS8 and ORF10 peptides were found elevated mainly among adults with mild (63%) symptoms. Antibodies towards S and N proteins of other coronaviruses (MERS, 229E, OC43, NL63 and HKU1) were detected in all groups without a significant correlation with SARS-CoV-2 antibody levels.

Conclusions: Overall, our results showed that antibodies elicited by specific linear epitopes of SARS-CoV-2 proteome are age dependent and related to COVID-19 clinical severity. Cross-reaction of antibodies to epitopes of other human coronaviruses was evident in all patients with distinct profiles between children and adult patients. Several SARS-CoV-2 peptides identified in this study are of particular interest for the development of vaccines and diagnostic tests to predict the clinical outcome of SARS-CoV-2 infection.

Files

2023-Journal of translational medicine.pdf

Files (6.7 MB)

Name Size Download all
md5:9dc61b7c77c8c1830f2db7169fb1e68e
1.6 MB Preview Download
md5:9fa51a8a54a3c3a8f63471a1e69fa261
1.3 MB Preview Download
md5:465ce430d3826db5da93b7dbc113d767
205.9 kB Preview Download
md5:408b6c2dc0b8338fd0dee1ff26ac8509
491.3 kB Preview Download
md5:3d720f0096d667099cf856dd419e8695
216.5 kB Preview Download
md5:6d0e134700ce8b1434549b64246a1373
441.0 kB Preview Download
md5:6508613634ca5e4e050b3d3bff41b650
478.8 kB Preview Download
md5:53cc0c464ff989789de38a533aee3572
434.4 kB Preview Download
md5:84d1678ad5abd94c635bca5d84152471
610.5 kB Preview Download
md5:6aee8c5d9c0936a425d98c9bca856fa7
433.1 kB Preview Download
md5:501356ad9e46a7689c0c9cf74233223c
420.9 kB Preview Download